Zydus Lifesciences Board Meeting on May 19, 2026 to Consider Equity Share Buyback Proposal

Zydus Lifesciences Limited has notified the BSE and the National Stock Exchange of India of an upcoming Board of Directors meeting scheduled for Tuesday, May 19, 2026. At this meeting, the Board will consider a proposal for the buyback of fully paid-up equity shares of the Company, along with all matters necessary and incidental thereto.

Board Meeting and Buyback Proposal

The intimation, issued on May 13, 2026, is in furtherance of an earlier communication dated May 8, 2026, regarding the scheduled Board meeting. The buyback proposal will be considered in accordance with the applicable provisions of the Companies Act, 2013 (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws.

The filing was made under Regulation 29(1)(b) and Regulation 29(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Parameter: Details Board Meeting Date: Tuesday, May 19, 2026 Intimation Date: May 13, 2026 Earlier Intimation Date: May 8, 2026 Proposal Under Consideration: Buyback of fully paid-up equity shares Applicable Regulation: Regulation 29(1)(b) and 29(2) of SEBI LODR Regulations, 2015

Trading Window Closure

In connection with the proposed buyback, the trading window as per the SEBI (Prohibition of Insider Trading) Regulations, 2015 will remain closed for all Directors and Designated Persons of the Company until Thursday, May 21, 2026. The trading window will reopen for trading on and from Friday, May 22, 2026.

The trading window is also deemed to be closed with respect to the aforementioned buyback proposal, in accordance with applicable laws.

Trading Window Status: Date Window Closed Until: Thursday, May 21, 2026 Window Reopens From: Friday, May 22, 2026

Filing Details

The regulatory filing was signed by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063) of Zydus Lifesciences Limited. The Company is headquartered at Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Ahmedabad, Gujarat.

Zydus Lifesciences Limited has notified the stock exchanges of an upcoming Board of Directors meeting, pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting is scheduled for Tuesday, May 19, 2026, and will take up, among other agenda items, key financial and dividend-related decisions for the recently concluded fiscal year. Following the results announcement, the company has also scheduled a post-results Q&A earnings call on the same day, pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (LODR) Regulations, 2015.

Board Meeting Agenda

The Board meeting has been convened to consider two primary items of business, as communicated through the official regulatory filing dated May 8, 2026:

Approval of audited financial results for the quarter and year ended March 31, 2026

Recommendation of final dividend for the Financial Year ended March 31, 2026

The following table summarizes the key details of the scheduled Board meeting:

Parameter: Details Meeting Date: Tuesday, May 19, 2026 Purpose: Approval of audited Q4FY26 financial results Additional Agenda: Recommendation of final dividend for FY ended March 31, 2026 Regulatory Reference: Regulation 29(1) of SEBI (LODR) Regulations, 2015 Filing Date: May 8, 2026

Q4 FY26 Post-Results Earnings Call

Zydus Lifesciences has scheduled a post-results Q&A session through a webinar on Tuesday, May 19, 2026, at 4:00 PM IST (Indian Standard Time). The earnings call for Q4 2025-26 (January–March 2026) will be hosted by Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited. The audio recording of the earnings call and the subsequent transcript will be made available on the company's website at www.zyduslife.com/investorzone .

Parameter: Details Earnings Call Date: Tuesday, May 19, 2026 Time: 4:00 PM IST Host: Dr. Sharvil Patel, Managing Director Format: Webinar (Zoom) Pre-Registration Link: https://bit.ly/4wo3Oyi Regulatory Reference: Regulation 30(6), Part A of Schedule III, SEBI (LODR) Regulations, 2015 Filing Date: May 13, 2026

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company has also communicated the applicable trading window restrictions for its Directors and Designated Persons. The trading window will remain closed until Thursday, May 21, 2026, and will reopen for trading on and from Friday, May 22, 2026.

Parameter: Details Trading Window Closure: Until Thursday, May 21, 2026 Trading Window Reopens: Friday, May 22, 2026 Applicable To: All Directors and Designated Persons of the Company

Regulatory Filing Details

The intimations were submitted by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063), on behalf of Zydus Lifesciences Limited. The company is registered at 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India, with CIN: L24230GJ1995PLC025878. The filings were made simultaneously to BSE Limited and the National Stock Exchange of India Limited, in compliance with applicable listing regulations.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.